Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.

Blood advances

Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, Jones N, Carvidi AB, Munter S, Bakkour S, Busch MP, Milush JM, Deeks SG, Henrich TJ. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv. 2018 Dec 11; 2(23):3479-3482.

2018
https://researcherprofiles.org/profile/33795930
30530753

Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, Jones N, Carvidi AB, Munter S, Bakkour S, Busch MP, Milush JM, Deeks SG, Henrich TJ

Publications

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.

Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD

1999
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.

Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD

1999
Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection.

Brander C, Goulder PJ, Luzuriaga K, Yang OO, Hartman KE, Jones NG, Walker BD, Kalams SA

1999
Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection.

Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, Korber B, Wentworth P, Buchbinder SP, Wolinsky S, Walker BD, Kalams SA

1998